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Abstract – According to the data obtained from in vivo and in vitro testing in Serbia, a significant number of patients have 
allergic symptoms caused by grass pollen. We examined the protein composition of grass pollens (Dactylis glomerata, 
Lolium perenne and Phleum pratense) and cross-reactivity in patients allergic to grass pollen from our region. The grass 
pollen allergen extract was characterized by SDS-PAGE, while cross-reactivity of single grass pollens was revealed by im-
munoblot analysis. A high degree of cross-reactivity was demonstrated for all three single pollens in the sera of allergic 
patients compared to the grass pollen extract mixture. Confirmation of the existence of cross-reactivity between different 
antigenic sources facilitates the use of monovalent vaccines, which are easier to standardize and at the same time prevent 
further sensitization of patients and reduces adverse reactions.
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INTRODUCTION
Grasses constitute a huge family, with around 8 000 
species. They are very widespread, probably covering 
about 20% of the world’s surface. 
Various conditions are required for a plant to 
cause pollinosis, such as the capability to distribute 
pollen by wind, to produce allergenic pollen in suffi-
cient quantities, and its proximity to humans (Vieira, 
2002).
Worldwide, at least 40% of allergic patients are 
sensitized to grass pollen allergens (Freidhoff et al., 
1986: Anderson and Lidholm, 2003). Thus, a variety 
of pollen-producing grasses have been recognized as 
allergenic, including Lolium perenne, Poa pratensis, 
Phleum  pratense,  Dactylis  glomerata  and  Cynodon 
dactylon (Weber, 2003). Lolium perenne and related 
grasses are significant sources of allergens in temper-
ate climate regions in North America, Europe and in 
parts of Australia (Vieira, 2002; Smart et al., 1979; 
Wüthrich et al., 1995). 
Patients  with  grass  pollen  allergy,  commonly 
called pollinosis, often manifest reactivity to pollen 
allergens from a number of grass species due to cross-
reactivity of IgE antibodies to pollen proteins present 
in pollen grasses. An extensive cross-reactivity among 
the different individual species of the genus could be 
expected, as well as, to a certain degree, among mem-
bers of the family Poaceae, most likely in members of 
the subfamily Pooideae (Dactylis glomerata, Festuca 
elatior, Phleum pretense, Lolium perenne, Poa pratensis, 
Alopecurus pratensis, Agrostis stolonifera), (Wüthrich 
et al., 1995; Anderson and Lidholm, 2003).1150 IVANA ALEKSIĆ ET AL.
Pollen allergens produce clinical symptoms after 
contact with the airway mucosa and the conjunctiva 
of previously sensitized individuals. Pollen allergen 
sensitization  may  occur  in  isolation  or  associated 
with sensitization to other perennial allergens, such 
as household dust mite allergens (Dermatophagoides 
pteronyssinus, Dpt).
Developments in studies on allergen sensitization 
and characterization have increased our understand-
ing of the grass pollen allergen sensitization process 
in sensitive individuals. A very important step in the 
diagnosis of allergic diseases is in vivo skin prick test-
ing, performed usually with crude extracts. These ex-
tracts are also used for specific immunotherapy with 
allergens, although in the case of grass pollen, aller-
gen potency may vary according to the environmen-
tal plant cultivation conditions in species of the same 
subfamily, the degree of maturity of pollen grains, 
extraction procedure and extract stability (Nieder-
berger at al, 1998). There is a trend among allergen 
extract companies to diminish the number of indi-
vidual extracts available for commercial use (Weber, 
2008; Mothes et al., 2004).
Cross-reactivity  can  be  explained  in  reference 
to biological taxonomy. The premise is that closely 
related plants will have a greater number of shared 
antigens than distantly related ones.
Cloning of recombinant allergens has helped in 
the identification and confirmation of homologous 
proteins and has clarified their functions. It has been 
suggested that protein content, or molecular classifi-
cation, is a superior way to address cross-reactivity 
issues rather than botanical taxonomy (Mothes et al., 
2004). Even though members of profilins and other 
major classes of grass pollens allergens contain high 
amino acid sequence homology, they do not always 
show strong cross-reactivity. 
Thirteen grass pollen allergen groups have been 
described as relevant antigens. Clinically, group 1 al-
lergens are the most important, and are recognized by 
approximately 95% of grass pollen sensitive patients, 
followed by group 5 allergens, which are recognized 
by up to 85% of these patients (Weber, 2003). Other 
clinically relevant allergens are those of groups 2, 3, 
4 and 13, which are recognized by over 50% of grass 
pollen-allergic individuals (Fahlbusch et al., 1998). 
When choosing allergens for immunotherapy and in 
vivo diagnosis, one should be guided by regional fac-
tors such as the prevalence of vegetation and climate. 
Dactylis glomerata, Phleum pretense and Lolium per-
enne are a frequent cause of allergies in our region. 
According to the data obtained from in vivo and in 
vitro testing in Serbia, a significant number of pa-
tients have allergic symptoms caused by grass pollen 
(Burazer et al., 2004), and most of them are subjected 
to grass pollen immunotherapy. 
The aim of this study is to investigate the compo-
sition of the grass pollen protein extracts from our 
area and the existence of cross-reactivity in patients 
allergic to grass pollens, in order to optimize in vivo 
diagnosis and specific immunotherapy.
MATERIALS AND METHODS
Skin prick testing
Skin prick testing was performed with a standard 
battery of glycerinated extracts (grass, tree and weed 
pollen, home dust, bed-linen dust, animal hair, mold, 
bacteria, bee venom, wasp venom, hornet venom, 
cockroach, and single pollens: Dactylis glomerata, 
Phleum pretense and Lolium perenne, all from the 
Institute for Virology, Vaccines and Sera “Torlak”, 
Belgrade, Serbia). Histamine phosphate at 1 mg/mL 
and PBS were used as positive and negative control, 
respectively.  The  results  of  skin  prick  tests  were 
evaluated after 20 min and a wheal of at least 3 × 3 
mm was considered positive.
Specific IgE (sIgE) detection
Specific  IgE  (sIgE)  detection  of  patients’  sera  was 
performed  by  ImmunoCAP-100  System  analysis 
(Thermo  Fisher  Scientific,  Uppsala,  Sweden).  The 
results were expressed in kUA/L and as CAP scores 
from class 0 to 6, according to the manufacturer’s in-
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SDS-PAGE and Western blot
SDS-PAGE was carried out according to Laemmli 
(1970) using a SE 600 Ruby scientific instrumenta-
tion apparatus with a discontinuous buffer system. 
Samples were boiled for 5 min before the run. About 
16 µg/well of proteins was resolved on a 13% gel at 80 
V for 1 h and 250 V for another 2 h. Either the gel was 
stained with Coomassie Brilliant Blue R-250 (CBB) 
to visualize the separated proteins or resolved com-
ponents were blotted by a semi-dry electrotransfer 
onto the nitrocellulose membrane (0.45 µm, Serva, 
Heidelberg, Germany). The membrane was blocked 
in 20 mM Tris-buffered saline (TBS) containing 1 % 
BSA and 0.1 % Tween 20 for 1 h and dried until de-
velopment.
IgE detection
IgE-binding proteins were detected by Western blot 
analysis with 5-fold diluted individual patient’s sera, 
or sera from non-allergic individuals in PBS contain-
ing 0.01% v/v Tween 20 (TPBS) with 0.1 % BSA. Al-
kaline phosphatase-labeled monoclonal anti-human 
IgE (Sigma Chemical Co., St Louis MO, USA) was 
used as the secondary antibody. The binding pat-
terns were visualized with a substrate solution of 1.5 
mg  BCIP  (5-bromo-4-chloro-3-indolyl  phosphate, 
Serva, Heidelberg, Germany) and 3 mg NBT (nitro 
blue  tetrazolium,  Serva,  Heidelberg,  Germany)  in 
10 mL of 100 mM Tris buffer, containing 150 mM 
NaCl, and 5 mM MgCl2, pH 9.6 according to Harlow 
& Lane (Harlow and Lane, 1990).
RESULTS
The data obtained from patients included in immu-
notherapy in 2010 and 2011 show that grass pollen 
stands out as the second relevant cause of allergic 
conditions in Serbia. The major cause of allergy in 
patients that underwent immunotherapy is house-
hold dust mite allergens – Dpt (758/2010 and 830 
/2011), compared to the number of affected patients 
who received immunotherapy for group grass pollen 
allergy (311/2010 and 298/2011) (Fig. 1).
The number of patients receiving therapy for in-
dividual grass pollens (monovalent vaccines) is pre-
sented in Fig. 2. The most frequent immunotherapy 
is for Dactylis glomerata grass species.
Qualitative analysis of allergen extracts (Phleum 
pretense,  Lolium  perenne  and  Dactylis  glomerata) 
used for in vivo diagnostics and immunotherapy is 
presented in Fig. 3. SDS-PAG electrophoresis of sam-
ples showed the existence of protein strips ranging 
from 10 to 116 kDa with the most prominent protein 
bands on 65, 60, 35, 18 and 10 kDa in all 3 extracts. 
Those protein bands are marked as major allergens 
(groups 1, 4, 5, 6, 11 and 13) and are in accordance 
with the literature data (Morata et al., 2005). 
The allergen profile of single pollen extracts was 
tested by immunoblotting using the sera of patients 
allergic to a mixture of grass pollen and to individual 
pollen  extracts  of Dactylis  glomerata, Phleum  pre-
tense and Lolium perenne. 
Fig. 4 shows the IgE immunoreactivity of each 
patient’s sera (sIgE levels were measured by Immu-
noCap test against a mixture of grass pollen extracts) 
towards  proteins  from  Dactylis  glomerata,  Phleum 
pretense and Lolium perenne antigenic extracts. The 
immunoreactive pattern is almost identical within 
a patient group for each of the three grass pollen 
extracts,  but  differs  substantially  between  Dactylis 
glomerata, Phleum pretense and Lolium perenne an-
tigenic extracts. 
Fig. 5 presents the IgE immunoreactivity of in-
dividual  patient’s  sera  (sIgE  levels  were  measured 
by ImmunoCap test against individual grass pollen 
extracts) towards proteins from Dactylis glomerata, 
Phleum pretense and Lolium perenne antigenic ex-
tracts. Fig. 5 shows the immunoblots of patients al-
lergic to a single grass pollen species (as shown by 
ImmunoCap test) against the SDS-PAGE pattern of 
individual grass pollen extracts (e.g. serum of pa-
tient allergic to Dactylis glomerata pollen extract was 
blotted against same extract and the same stands for 
other two extracts). Fig. 6 clearly demonstrates what 
could be anticipated from Fig. 4, which is cross re-1152 IVANA ALEKSIĆ ET AL.
activity between Phleum pretense and each of afore-
mentioned extracts, namely Dactylis glomerata and 
Lolium perenne.
DISCUSSION
The presence of grass pollens, as one of the prevailing 
causes of allergy, varies worldwide depending on the 
climate zone. It has been proposed that, due in part 
to the varied species geography, exposure conditions 
and patient diversity, no single immunotherapeutic 
approach can be successful in every patients. The 
most important group of grass pollens is from the 
Pooideae grass species, among which there is cross-
reactivity. Traditionally, grass pollen-allergic subjects 
have been treated with extracts of a combination of 
grass pollen extracts from different species, which 
contain large numbers of allergenic proteins.
Grass  pollen  allergens  may  present  shared 
epitopes  that  are  responsible  for  cross-reactivity. 
Thirteen groups of pollen are described, of which 
the most important are 1, 5, 3, 4, 2 and 13. Clini-
cally, group 1 allergens are the most important, and 
are recognized by approximately 95% of grass pol-
len sensitive patients, followed by group 5 allergens, 
which are recognized by up to 85% of these patients 
fig. 1. The number of patients receiving immunotherapy ac-
cording to the allergy causative agents (2010/2011).
fig. 3. Separation of pollen extracts - Phleum pratense, Lolium 
perenne and Dactylis glomerata by SDS-PAGE on a 13% poly-
acrylamide gel. MW – molecular mass markers.
fig. 2. The number of patients receiving monovalent vaccines 
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(Weber,  2003).  Other  clinically  relevant  allergens 
are those of groups 2, 3, 4 and 13, which are recog-
nized by over 50% of grass pollen allergic individuals 
(Fahlbusch et al., 1998).
Specific  immunotherapy  (SIT)  is  recognized, 
aside from allergen avoidance, as the only treatment 
“that may affect the natural course of allergic diseases” 
(Bousquet, 1998). This treatment refers to IgE-me-
diated allergic diseases. Sublingual immunotherapy 
(SLIT) for grass pollen-induced rhinoconjunctivitis 
has been developed to make immunotherapy avail-
able to a broader group of allergic patients. Many im-
munotherapies are manufactured from natural raw 
materials or crude extracts.
The allergen content of crude extracts may vary 
not only among different grass species and allergen 
isoforms, but also according to pollen maturity, al-
lergen  extraction  procedures  and  extract  stability 
fig. 6. IgE reactivity from patients’ sera allergic to individual 
grass pollen extracts (Dactylis glomerata, Lolium perenne) to-
wards corresponding pollen protein extracts from Dactylis glom-
erata, Lolium perenne and Phleum pratense. MW – molecular 
mass markers.
fig. 4. IgE reactivity from patients’ sera allergic to a mix of grass 
pollen extracts and blotted against individual Dactylis glomerata, 
Lolium perenne and Phleum pratense protein extracts. MW – 
molecular mass markers.
fig. 5. IgE reactivity from patients’ sera allergic to individual 
grass pollen extracts and blotted against its corresponding pol-
len protein extract from Dactylis glomerata, Lolium perenne and 
Phleum pratense. MW – molecular mass markers.1154 IVANA ALEKSIĆ ET AL.
(Niederberger, 1998). Quantification of the main al-
lergens  contained  in  extracts  and  characterization 
of the main grass allergens, including isoforms, are 
important to develop allergen extracts to optimize 
the diagnosis and immunotherapy in sensitized pa-
tients.
Cross-reactivity  between  different  pollen  anti-
gens helps us understand and simplify allergens for 
in vivo diagnosis and immunotherapy. Natural grass 
pollen allergens exhibit a wide variety of isoforms. 
Precise characterization of such microheterogeneity 
is essential to improve diagnosis and design appro-
priate immunotherapies. Moreover, standardization 
of allergen vaccine production is a prerequisite for 
product safety and efficiency.
Our data suggest that there is a high percentage 
of cross-reactivity between the allergens from Dac-
tylis glomerata, Phleum pretense and Lolium perenne 
that were tested compared to the mixture of grass 
pollens and to single pollens using the sera of pa-
tients from our region. The data provide us with the 
possibility of monovalent immunotherapy applica-
tion instead of the recent practice, based on therapy 
using different grass-pollen mixtures. There appears 
to be no significant differences between single spe-
cies extracts and mixes (Hajl et al 2009). However, 
cross-reactivity has been confirmed for both IgE and 
IgG4. IgE is responsible for allergic symptoms, and 
the shift in balance from a predominant IgE response 
to one based primarily on other antibody isotypes is 
intrinsic to the effect of immunotherapy (Larche et 
al., 2006; Flicker and Valenta, 2003).
Vaccines prepared from a larger number of pol-
lens are difficult to standardize and control as a prod-
uct. When polyvalent vaccines are used, there is a 
possibility of additional sensitization of patients due 
to their exposure to a large number of antigens. The 
importance  of  monocomponent  vaccines  can  due 
to  better  standardization,  significant  reduction  in 
adverse reactions and improved immune response. 
However, therapy should be designed to contain a 
sufficient amount of major allergens and that treat-
ment may include wide population of sensitized pa-
tients.
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